Cell-Based Therapies for Solid Tumors: Challenges and Advances
International Journal of Molecular Sciences · 09.06.2025 · 26 (12) · 5524
DOI: 10.3390/ijms26125524 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift International Journal of Molecular Sciences, online erschienen am 09.06.2025. Verfasst von Anna Smolarska und 6 weiteren Autor:innen. Beteiligte Einrichtung: Center of Cellular Immunotherapies, Warsaw University of Life Sciences, 02-787 Warsaw, Poland. Hauptthemen laut MEDLINE: Neoplasms, Immunotherapy, Adoptive, Cell- and Tissue-Based Therapy. Die Arbeit wurde bisher 16-mal zitiert (Crossref) und nennt 140 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Science Development Fund of the Warsaw University of Life Sciences—SGGW.
Abstract (Originalsprache)
Solid tumors pose significant therapeutic challenges due to their resistance to conventional treatments and the complexity of the tumor microenvironment. Cell-based immunotherapies offer a promising approach, enabling precise, personalized treatment through immune system modulation. This review explores several emerging cellular therapies for solid tumors, including tumor-infiltrating lymphocytes, T cell receptor-engineered T cells, CAR T cells, CAR natural killer cells, and macrophages. Tumor-infiltrating lymphocytes and their modified versions, T cell receptor-engineered T cells and CAR T cells, provide personalized immune responses, although their effectiveness can be limited by factors like variation in tumor antigens and the suppressive nature of the tumor environment. Natural killer cells engineered with chimeric receptors offer safer, non-major histocompatibility complex-restricted targeting, while modified macrophages exploit their natural ability to enter tumors and reshape the immune landscape. CAR-modified macrophages and macrophages conjugated with drugs are also considered as therapy for solid tumors. The review also examines the implications of autologous versus allogeneic cell sources. Autologous therapies ensure immunologic compatibility but are limited by scalability and manufacturing constraints. Allogeneic approaches offer “off-the-shelf” potential but require gene editing to avoid immune rejection. Integrating synthetic biology, gene editing, and combinatorial strategies will be essential to enhance efficacy and expand the clinical utility of cellular immunotherapies for solid tumors.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Center of Cellular Immunotherapies, Warsaw University of Life Sciences, 02-787 Warsaw, Poland.
- Faculty of Biology and Biotechnology, Warsaw University of Life Sciences, 02-787 Warsaw, Poland.
Förderung
- Science Development Fund of the Warsaw University of Life Sciences—SGGW
Zitieren
APA
Smolarska, A., Kokoszka, Z., Naliwajko, M., Strupczewska, J., Tondera, J., Wiater, M., & Orzechowska, R. (2025). Cell-Based Therapies for Solid Tumors: Challenges and Advances. International Journal of Molecular Sciences, 26(12), 5524. https://doi.org/10.3390/ijms26125524
Vancouver
Smolarska A, Kokoszka Z, Naliwajko M, Strupczewska J, Tondera J, Wiater M, et al. Cell-Based Therapies for Solid Tumors: Challenges and Advances. International Journal of Molecular Sciences. 2025;26(12):5524. doi:10.3390/ijms26125524
BibTeX
@article{Smolarska2025,
author = {Smolarska, Anna and Kokoszka, Zuzanna and Naliwajko, Marcelina and Strupczewska, Julia and Tondera, Jędrzej and Wiater, Maja and Orzechowska, Roksana},
title = {Cell-Based Therapies for Solid Tumors: Challenges and Advances},
journal = {International Journal of Molecular Sciences},
year = {2025},
volume = {26},
number = {12},
pages = {5524},
doi = {10.3390/ijms26125524}
}
EUVIMED